

# Martin Bak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5501724/publications.pdf>

Version: 2024-02-01

23  
papers

530  
citations

567281  
15  
h-index

677142  
22  
g-index

24  
all docs

24  
docs citations

24  
times ranked

929  
citing authors

#	ARTICLE	IF	CITATIONS
1	High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5514-5526.	7.0	57
2	Pleomorphic (giant cell) carcinoma of the intestine. An immunohistochemical and electron microscopic study. <i>Cancer</i> , 1989, 64, 2557-2564.	4.1	52
3	Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers. <i>Breast Cancer Research</i> , 2015, 17, 55.	5.0	49
4	Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis. <i>Oncotarget</i> , 2015, 6, 5634-5649.	1.8	42
5	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. <i>Nature Communications</i> , 2021, 12, 5112.	12.8	38
6	SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 60.	5.0	36
7	Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment. <i>PLoS ONE</i> , 2015, 10, e0118346.	2.5	24
8	Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. <i>BMC Cancer</i> , 2015, 15, 239.	2.6	24
9	Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence. <i>Scientific Reports</i> , 2017, 7, 43813.	3.3	24
10	Identification of metastasis driver genes by massive parallel sequencing of successive steps of breast cancer progression. <i>PLoS ONE</i> , 2018, 13, e0189887.	2.5	24
11	Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancer. <i>Oncotarget</i> , 2018, 9, 9030-9042.	1.8	22
12	Existing data sources for clinical epidemiology: the Danish Quality Database of Mammography Screening. <i>Clinical Epidemiology</i> , 2013, 5, 81.	3.0	20
13	100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype. <i>International Journal of Cancer</i> , 2015, 137, 2093-2103.	5.1	19
14	Sentinel Node Localization in Breast Cancer Patients Using Intradermal Dye Injection. <i>Acta Oncologica</i> , 2000, 39, 423-428.	1.8	18
15	miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations. <i>Oncotarget</i> , 2015, 6, 29224-29239.	1.8	18
16	CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients. <i>International Journal of Cancer</i> , 2019, 144, 631-640.	5.1	17
17	Outcome of breast cancer screening in Denmark. <i>BMC Cancer</i> , 2017, 17, 897.	2.6	16
18	Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1 $\alpha$ ,25-dihydroxyvitamin D3. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 177, 171-178.	2.5	10

#	ARTICLE	IF	CITATIONS
19	MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. Npj Breast Cancer, 2021, 7, 2.	5.2	7
20	Morbidity as a Predictor for Participation in the Danish National Mammography Screening Program: A Cross-Sectional Study. Clinical Epidemiology, 2020, Volume 12, 509-518.	3.0	5
21	Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer. BMC Cancer, 2018, 18, 1226.	2.6	3
22	Breast cancer stem cells: a moving target for cancer nanomedicine. European Journal of Nanomedicine, 2012, 4, 59-72.	0.6	1
23	Comparison of the Metastasis Predictive Potential of mRNA and Long Non-Coding RNA Profiling in Systemically Untreated Breast Cancer. Cancers, 2021, 13, 4907.	3.7	0